Your browser is no longer supported. Please, upgrade your browser.
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.26 Insider Own2.81% Shs Outstand4.86M Perf Week-18.92%
Market Cap35.19M Forward P/E- EPS next Y-1.87 Insider Trans0.00% Shs Float3.06M Perf Month-6.63%
Income-8.10M PEG- EPS next Q-0.52 Inst Own45.60% Short Float33.50% Perf Quarter95.47%
Sales- P/S- EPS this Y20.50% Inst Trans474.79% Short Ratio1.12 Perf Half Y69.12%
Book/sh5.02 P/B1.37 EPS next Y27.00% ROA-38.50% Target Price- Perf Year-36.49%
Cash/sh4.53 P/C1.52 EPS next 5Y- ROE-44.60% 52W Range3.12 - 19.25 Perf YTD-11.65%
Dividend- P/FCF- EPS past 5Y46.00% ROI- 52W High-64.16% Beta1.29
Dividend %- Quick Ratio15.10 Sales past 5Y- Gross Margin- 52W Low121.15% ATR0.88
Employees12 Current Ratio15.10 Sales Q/Q- Oper. Margin- RSI (14)40.88 Volatility12.52% 12.69%
OptionableNo Debt/Eq0.00 EPS Q/Q79.10% Profit Margin- Rel Volume0.43 Prev Close7.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume914.95K Price6.90
Recom1.70 SMA20-16.07% SMA50-9.46% SMA20037.40% Volume394,794 Change-1.43%
Apr-27-20Resumed ROTH Capital Buy $24
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Nov-27-07Reiterated Cantor Fitzgerald Buy $14 → $10.50
Aug-10-07Reiterated Cantor Fitzgerald Buy $12 → $14
Jun-04-07Reiterated Needham & Co Buy $9 → $12
Apr-23-07Initiated Lazard Capital Buy $11
Apr-10-07Initiated Cantor Fitzgerald Buy $12
Feb-25-21 04:05PM  
Feb-19-21 07:00AM  
Feb-10-21 07:00AM  
Feb-01-21 10:05PM  
Jan-11-21 07:46AM  
Dec-30-20 07:00AM  
Dec-22-20 08:00AM  
Dec-21-20 07:00AM  
Nov-11-20 04:05PM  
Nov-05-20 09:29AM  
Oct-26-20 08:26AM  
Oct-23-20 04:30PM  
Oct-05-20 07:00AM  
Sep-21-20 07:00AM  
Aug-16-20 04:26AM  
Aug-12-20 04:05PM  
Aug-05-20 07:00AM  
Jul-28-20 11:46AM  
Jul-13-20 07:00AM  
May-21-20 09:22AM  
May-12-20 04:05PM  
May-05-20 07:00AM  
Apr-24-20 04:05PM  
Apr-21-20 12:59PM  
Apr-20-20 07:00AM  
Apr-14-20 12:30PM  
Mar-17-20 07:17AM  
Mar-12-20 12:13AM  
Feb-26-20 04:05PM  
Feb-20-20 08:50AM  
Feb-19-20 07:00AM  
Feb-10-20 08:53AM  
Feb-03-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-11-19 06:13AM  
Dec-09-19 07:00AM  
Dec-04-19 07:18AM  
Nov-13-19 04:05PM  
Nov-07-19 07:00AM  
Nov-06-19 09:00AM  
Oct-12-19 09:44AM  
Sep-23-19 07:00AM  
Sep-09-19 07:00AM  
Sep-04-19 07:00AM  
Sep-03-19 12:30PM  
Aug-28-19 12:34PM  
Aug-13-19 04:05PM  
Aug-11-19 03:46PM  
Aug-07-19 07:00AM  
Jul-22-19 07:00AM  
Jul-04-19 06:49AM  
Jun-26-19 02:59PM  
May-24-19 12:50PM  
May-14-19 04:05PM  
May-08-19 07:00AM  
Apr-29-19 09:55AM  
Apr-09-19 11:05AM  
Apr-01-19 07:00AM  
Mar-27-19 04:05PM  
Mar-26-19 12:46PM  
Mar-25-19 07:00AM  
Mar-20-19 07:00AM  
Mar-13-19 07:00AM  
Mar-05-19 07:00AM  
Feb-05-19 07:00AM  
Jan-24-19 07:25AM  
Jan-07-19 07:00AM  
Jan-03-19 11:11PM  
Dec-27-18 07:00AM  
Dec-25-18 02:25PM  
Dec-04-18 07:35AM  
Nov-13-18 07:54AM  
Nov-12-18 04:05PM  
Nov-06-18 07:00AM  
Oct-25-18 08:30AM  
Oct-23-18 07:00AM  
Oct-04-18 07:00AM  
Sep-26-18 07:00AM  
Sep-20-18 01:01PM  
Sep-12-18 07:00AM  
Sep-10-18 07:00AM  
Sep-05-18 07:30AM  
Aug-29-18 07:00AM  
Aug-27-18 09:45PM  
Aug-16-18 08:15AM  
Aug-09-18 04:05PM  
Aug-01-18 07:00AM  
May-25-18 02:09PM  
May-21-18 05:23PM  
May-14-18 04:05PM  
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.